Authors : Maha Raja Dahar; Noor Nabi; Makhdoom Bilawal; Muhammed Qasim Barkat; Zareen Taj; Shamu Aiman; Noori; Lushan Yu

Volume/Issue : Volume 9 - 2024, Issue 9 - September

Google Scholar : https://tinyurl.com/2pmenjxm

Scribd : https://tinyurl.com/um2shxuh

DOI : https://doi.org/10.38124/ijisrt/IJISRT24SEP1479

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background Antimicrobial abuse is connected to the emergence and dissemination of drug-resistant pathogens, as well as other problems. Morbidity, death, hospital stay periods, and healthcare costs have all risen. Antimicrobial stewardship is an overarching word for a holistic quality management approach involving evidence-based information exchange programs to optimize the usage of antimicrobials, enhance patient outcomes, minimize antimicrobial resistance, and hospital-acquired infections including Clostridium difficile, and lower healthcare costs. Antimicrobial stewardship program (ASP) aims to prevent or slow the emergence of antimicrobial resistance, optimize the selection, dosing, and duration of antimicrobial therapy, reduce the incidence of drug-related adverse events, and reduce rates of morbidity and mortality, length of hospital stay, and costs by evaluating and improving how antimicrobial agents are selected and delivered. This study was conducted in three different hospitals, from each hospital 100 patient profiles were evaluated to compare the effectiveness and benefits of the antibiotic stewardship program. A pre-designed intervention form is used for the assessment to evaluate patients' profile / Computerized Physician order entries / Manual prescriptions which contain at least one or more kinds of antibiotics. In this study, some parameters were observed as there is a total 18 number of antibiotics mostly prescribed to patients, however, in small rural hospitals there were large spectrum antibiotics were prescribed more without justification, however in tertiary care hospitals, the selection of antibiotics is based on the patient’s need, beyond that it was observed that mostly drug resistance cases occur in a small rural hospital and a small urban hospital as compared to a large tertiary hospital. Further, it was evaluated that eight different Drug-related problems (prescribing) were associated with improper use of antibiotics. i.e. the excessive duration of therapy, culture sensitivity (C/S) not followed, culture sensitivity (C/S) not Reported, high dose prescribed, and therapeutic drug monitoring (TDM) not reported, Through this study that is evaluated that in large tertiary care hospitals, ASP implemented effectively so due to that there were 25257 PKR was saved on each patient which was the cost of unwanted therapy, but in a small rural hospital and the small suburban hospital where there is no any concept of ASP, and there is no any restriction to prescribe unwanted antibiotics, due to that reason there was no saved cost at these type of hospitals.  Conclusion With the help of this limited study it was concluded that in tertiary care hospitals (where ASP was implemented) there was optimum use of antibiotics, cases of bacterial resistance were not much more, and here clinical outcomes of patients were observed more but as compare to this in a small rural hospital and small suburban hospital there were unethical use of antibiotics were observed, and no any restriction and limitations are observed toprescribe and dispense antibiotics. Instead of this, that was also observed that in tertiary care hospitals, the extra cost was saved due to short stays and proper use of antibiotics, but there was no saving in other hospitals where ASP was not implemented. So finally this is to conclude that ASP has more benefits and must be implemented in every healthcare setup.

Keywords : Antibiotics Stewardship, Clinical Pharmacy, Pharmacoeconomics, Pharmacist.

References :

1. S. Doron and L. E. Davidson, “Antimicrobial stewardship,” Mayo Clin. Proc., vol. 86, no. 11, pp. 1113–1123, 2011, doi: 10.4065/mcp.2011.0358.
2. P. H. Service and H. Services, “National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004,” Am. J. Infect. Control, vol. 32, no. 8, pp. 470–485, 2004, doi: 10.1016/j.ajic.2004.10.001.
3. M. Infections et al., “Health Care – Associated Invasive MRSA,” vol. 304, no. 6, pp. 2005–2008, 2012.
4. M. Gilchrist, E. T. Brannigan, G. Satta, and M. Laundy, “Antibiotic stewardship in the intensive care unit,” Antibiot. Pharmacokinet. Considerations Crit. Ill, pp. 265–275, 2017, doi: 10.1007/978-981-10-5336-8_13.
5. T. T. H. Dat and P. T. T. Oanh, “Pharmacological activities and volatile organic compounds from the endophytic bacteria from the leaves of Rhizophora Apiculata,” Bangladesh J. Pharmacol., vol. 16, no. 4, pp. 129–133, 2021, doi: 10.3329/bjp.v16i4.56682.
6. The General Assembly, “Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance : draft resolution / submitted by the President of the General Assembly,” a/71/L.2, vol. 16416, no. September, pp. 1–6, 2016.
7. T. Naimi, P. Ringwald, R. Besser, S. Thompson, and D. Bell, “Antimicrobial resistance,” Emerg. Infect. Dis., vol. 7, no. 3, p. 548, 2001, doi: 10.3201/eid0707.017727.
8. The John Hopkins Medical institution U.S.A, “Manual of antibiotic therapy developed by Department of Pediatric infectious diseases,” pp. 50–100, 2019.
9. H. A. Reimann, “Infectious diseases: Annual Review of Significant Publications,” A.M.A Arch. Intern. Med., vol. 98, no. 5, pp. 639–671, 2019, doi: 10.1001/archinte.1956.00250290099012.
10. M. R. Achong, B. A. Hauser, and J. L. Krusky, “Rational and irrational use of antibiotics in a Canadian teaching hospital,” Can. Med. Assoc. J., vol. 116, no. 3, pp. 256–259, 2014.
11. Patrick Choutet, “Antibiotic use: excesses and consequences,” 14, pp. 1527–32.
12. E. Schollenberg and W. L. Albritton, “Antibiotic misuse in a pediatric teaching hospital,” Can. Med. Assoc. J., vol. 122, no. 1, pp. 49–52, 2018, doi: 10.1007/bf03292366.
13. W. H. O. P. Toolkit, Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit, vol. 1, no. 3. 2019.
14. M. Rzewuska et al., “Prioritizing research areas for antibiotic stewardship programmes in hospitals: a behavioural perspective consensus paper,” Clin. Microbiol. Infect., vol. 25, no. 2, pp. 163–168, 2019, doi: 10.1016/j.cmi.2018.08.020.
15. Ertürk Şengel et al., “The need for an antibiotic stewardship program in a hospital using a computerized pre-authorization system,” Int. J. Infect. Dis., vol. 82, pp. 40–43, 2019, doi: 10.1016/j.ijid.2019.02.044.
16. D. S. of America, “Promoting antimicrobial stewardship in human medicine,” 2018.
17. M. J. L. 15 V A Schweitzer 1, C H van Werkhoven 1, J Rodríguez Baño 2, J Bielicki 3, S Harbarth 4, M Hulscher 5, B Huttner 4, J Islam 6, P Little 7, C Pulcini 8, A Savoldi 9, E Tacconelli 9, J-F Timsit 10, M van Smeden 11, M Wolkewitz 12, M J M Bonten 13, A S Walker, “Optimizing design of research to evaluate antibiotic stewardship interventions: consensus recommendations of a multinational working group,” DOI 10.1016/j.cmi.2019.08.017.
18. Ohl and E. S. Dodds Ashley, “Antimicrobial stewardship programs in community hospitals: The evidence base and case studies,” Clin. Infect. Dis., vol. 53, no. SUPPL. 1, pp. 23–28, 2011, doi: 10.1093/cid/cir365.
19. (ASHP), “A hospital Pharmacist guide. Published by American society of health professionals,” pp. 1–20, 2014.
20. J. Liu, F. Zhu, B. Feng, Z. Zhang, L. Liu, and G. Wang, “Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network,” J. Glob. Antimicrob. Resist., vol. 24, pp. 136–147, 2020, doi: 10.1016/j.jgar.2020.08.021.
21. P. Davey et al., “Interventions to improve antibiotic prescribing practices for hospital inpatients (updated protocol),” Cochrane Database Syst. Rev., vol. 2017, no. 2, 2017, doi: 10.1002/14651858.CD011236.pub2.
22. S. Tonkin-Crine, A. S. Walker, and C. C. Butler, “Contribution of behavioural science to antibiotic stewardship,” BMJ, vol. 350, no. June, 2015, doi: 10.1136/bmj.h3413.
23. R. M. Zetts, A. Stoesz, B. A. Smith, and D. Y. Hyun, “Outpatient antibiotic use and the need for increased antibiotic stewardship efforts,” Pediatrics, vol. 141, no. 6, 2018, doi: 10.1542/peds.2017-4124.
24. T. H. Dellit, “Summary of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship,” Infect. Dis. Clin. Pract., vol. 15, no. 4, pp. 263–264, 2007, doi: 10.1097/IPC.0b013e318068b1c0.
25. M. imitri Drekonja, MD, MS, Gregory Filice, MD, Nancy Greer, PhD, Andrew Olson, MD, Roderick MacDonald, MS, Indulis Rutks, BS, and Timothy J Wilt, MD, “Antimicrobial Stewardship Programs in Outpatient Settings,” Dep. Veterans Aff.
26. Kuruc Poje, V. Macrossed D Signarić, V. Janeš Poje, D. Kifer, P. Howard, and S. Marušić, “Antimicrobial stewardship effectiveness on rationalizing the use of last line of antibiotics in a short period with limited human resources: A single centre cohort study,” BMC Res. Notes, vol. 12, no. 1, pp. 10–15, 2019, doi: 10.1186/s13104-019-4572-x.
27. CDC, “Core elements of hospital antibiotic stewardship programs,” US Dep. Heal. Hum. Serv. CDC, p. 40, 2019.
28. T. F. Barlam et al., “Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America,” Clin. Infect. Dis., vol. 62, no. 10, pp. e51–e77, 2016, doi: 10.1093/cid/ciw118.
29. Centers for Disease Control and Prevention, “The Core Elements of Hospital Antibiotic Stewardship Programs. Antibiotic stewardship program assessment tool,” Centers Dis. Control Prev., 2019.
30. H. Services and D. Control, “2019 National Healthcare Safety Network Antimicrobial Use Option Report,” no. November, 2020.
31. The Joint Commission, “Joint Commission Medical Management Standard for Antimicrobial Stewardship,” Jt. Comm. Perspect., vol. 36, no. 7, pp. 1–8, 2016.
32. Goff, R. Kullar, K. A. Bauer, and T. M. File, “Eight habits of highly effective antimicrobial stewardship programs to meet the joint commission standards for hospitals,” Clin. Infect. Dis., vol. 64, no. 8, pp. 1134–1139, 2017, doi: 10.1093/cid/cix065.
33. Stenehjem et al., “Antibiotic Stewardship in Small Hospitals: Barriers and Potential Solutions,” Clin. Infect. Dis., vol. 65, no. 4, pp. 691–696, 2017, doi: 10.1093/cid/cix407.
34. L. Jeffs, N. Thampi, M. Maione, M. Steinberg, A. M. Morris, and C. M. Bell, “A qualitative analysis of implementation of antimicrobial stewardship at 3 academic hospitals: Understanding the key influences on success,” Can. J. Hosp. Pharm., vol. 68, no. 5, pp. 395–400, 2015, doi: 10.4212/cjhp.v68i5.1486.
35. J. C. McGregor and J. P. Furuno, “Optimizing research methods used for the evaluation of antimicrobial stewardship programs,” Clin. Infect. Dis., vol. 59, no. Suppl 3, pp. S185–S192, 2014, doi: 10.1093/cid/ciu540.
36. Phillips, “Prudent use of antibiotics: Are our expectations justified?,” Clin. Infect. Dis., vol. 33, no. SUPPL. 3, pp. 130–132, 2001, doi: 10.1086/321838.
37. L. D. Y. Wu, S. A. N. Walker, M. Elligsen, L. Paimay, A. Simor, and N. Daneman, “Antibiotic use and need for antimicrobial stewardship in long-term care,” Can. J. Hosp. Pharm., vol. 68, no. 6, pp. 445–449, 2015, doi: 10.4212/cjhp.v68i6.1500.
38. Huttner et al., “Antimicrobial resistance: A global view from the 2013 World Healthcare-Associated Infections Forum,” Antimicrob. Resist. Infect. Control, vol. 2, no. 1, 2013, doi: 10.1186/2047-2994-2-31.
39. E. M. Graffunder and R. A. Venezia, “Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials,” J. Antimicrob. Chemother., vol. 49, no. 6, pp. 999–1005, 2002, doi: 10.1093/jac/dkf009.
40. R. Kaki, M. Elligsen, S. Walker, A. Simor, L. Palmay, and N. Daneman, “Impact of antimicrobial stewardship in critical care: A systematic review,” J. Antimicrob. Chemother., vol. 66, no. 6, pp. 1223–1230, 2011, doi: 10.1093/jac/dkr137.
41. DiDiodato and L. McArthur, “Evaluating the effectiveness of an antimicrobial stewardship program on reducing the incidence rate of healthcare-associated clostridium difficile infection: A Non-randomized, stepped wedge, single-site, observational study,” PLoS One, vol. 11, no. 6, pp. 1–17, 2016, doi: 10.1371/journal.pone.0157671.
42. M. Giulio DiDiodato, MD and A. Leslie McArthur, RPh, “Interhospital patient transfers between Ontario’s academic and large community hospitals increase the risk of Clostridium difficile infection,” Am. J. Infect. Control, vol. VOLUME 46, no. ISSUE 2, pp. P191-196, 2018, doi: DOI:https://doi.org/10.1016/j.ajic.2017.08.018.
43. L. E. Nicolle, “Antimicrobial stewardship in long term care facilities: What is effective?,” Antimicrob. Resist. Infect. Control, vol. 3, no. 1, 2014, doi: 10.1186/2047-2994-3-6.
44. C.-C. Lai, “Evaluation of a Pediatric Antimicrobial Stewardship Program in a Tertiary Care Medical Center,” pp. 1–104, 2014.
45. L. Agwu et al., “A world wide web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center,” Clin. Infect. Dis., vol. 47, no. 6, pp. 747–753, 2008, doi: 10.1086/591133.
46. S. J. Patel, L. Saiman, J. M. Duchon, D. Evans, Y. H. Ferng, and E. Larson, “Development of an antimicrobial stewardship intervention using a model of actionable feedback,” Interdiscip. Perspect. Infect. Dis., vol. 2012, no. c, 2012, doi: 10.1155/2012/150367.
47. T. Lahey, R. Shah, J. Gittzus, J. Schwartzman, and K. Kirkland, “Infectious diseases consultation lowers mortality from staphylococcus aureus bacteremia,” Medicine (Baltimore)., vol. 88, no. 5, pp. 263–267, 2009, doi: 10.1097/MD.0b013e3181b8fccb.
48. V. Schechner, E. Temkin, S. Harbarth, Y. Carmeli, and M. J. Schwaber, “Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance,” Clin. Microbiol. Rev., vol. 26, no. 2, pp. 289–307, 2013, doi: 10.1128/CMR.00001-13.
49. K. L. Buising et al., “Electronic antibiotic stewardship - Reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting,” J. Antimicrob. Chemother., vol. 62, no. 3, pp. 608–616, 2008, doi: 10.1093/jac/dkn218.
50. J. F. John and N. O. Fishman, “Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital,” Clin. Infect. Dis., vol. 24, no. 3, pp. 471–485, 1997, doi: 10.1093/clinids/24.3.471.